Compare Americas Gold and Silver Corporation Common Shares no par value (USAS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Americas Gold and Silver Corporation Common Shares no par value vs Viatris Inc — how do they compare? Americas Gold and Silver Corporation Common Shares no par value trades at $3.76 (market cap $1.36B), while Viatris Inc trades at $17.59 (market cap $19.81B). The key difference: Viatris Inc is far larger — about 14.6× Americas Gold and Silver Corporation Common Shares no par value's market cap, and Viatris Inc pays a 2.78% dividend while Americas Gold and Silver Corporation Common Shares no par value pays none. Which is the better fit depends on your goals — on Pluang, investors hold Americas Gold and Silver Corporation Common Shares no par value for 0 Days and Viatris Inc for 57 Days on average.
| USAS | VTRS | |
|---|---|---|
Market Cap | $1.36B | $19.81B |
Volume | 3,177,621 | 7,547,542 |
Sector | Basic Materials | Health |
52-Week High | $10.03 | $18.27 |
52-Week Low | $3.59 | $9.98 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $1.29B | $31.92B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USAS trades at $4.02, down 4.29% on the day, reflecting ongoing volatility amid mixed operational performance. The company reported a net loss of $87.45M in 2025, though revenue is projected to grow to $182M in 2026 with a narrowing loss. Recent news highlights progress at its Galena and Cosalá mines, including high-grade silver discoveries and sustainability initiatives, signaling potential for future production growth.
The outlook is speculative, with high-risk turnaround potential driven by operational improvements and exposure to silver and critical minerals. Key risks include persistent negative profitability, high valuation multiples like EV/EBITDA of 455.68, and reliance on successful mine development. Analyst consensus is unanimously bullish, but investors must weigh execution risks against long-term growth prospects.
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $3.51B in 2025. Recent news highlights include FDA approval for WAKIX in Japan and recognition as a top employer. Analyst consensus is mixed with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but faces fundamental challenges including negative profit margins and high debt. Positive cash flow generation and consistent earnings beats provide support, while competitive pressures and execution risks remain concerns for investors seeking turnaround potential in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Americas Gold and Silver Corporation Common Shares no par value
Americas Gold and Silver Corporation is a Canada-based mining company that explores for and produces silver, along with by-product gold, copper, lead, and zinc. Its operating assets include the Galena Complex in Idaho and the Cosalá Operations in Sinaloa, Mexico.
Read more on USAS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
